Related Experiment Video

Updated: May 21, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma

Fabrizio Tabbó1, Antonella Barreca, Roberto Piva

  • 1Department of Pathology, Center for Experimental Research and Medical Studies, University of Torino Torino, Italy.

Frontiers in Oncology
|June 1, 2012
PubMed

Insights

Anaplastic lymphoma kinase (ALK) genetic lesions drive cancer transformation. Understanding ALK-mediated mechanisms aids in developing targeted therapies for specific cancer patient subsets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The t(2;5)(p23;q35) translocation discovery established molecular recognition of anaplastic large cell lymphoma.
  • Anaplastic lymphoma kinase (ALK) genetic lesions identify distinct cancer patient subsets.

Purpose of the Study:

  • To review the molecular mechanisms of ALK-mediated transformation.
  • To understand ALK's role in maintaining the neoplastic phenotype.
  • To guide novel therapeutic strategies for ALK-driven cancers.

Main Methods:

  • Literature review of ALK-mediated transformation.
  • Analysis of genetic lesions in human cancers.
  • Molecular mechanism appraisal.

Main Results:

  • ALK genetic lesions are crucial in various human cancers.
  • ALK drives neoplastic transformation and phenotype maintenance.
  • Identification of ALK-driven subsets enables targeted therapies.

Conclusions:

  • Understanding ALK's molecular role is key for cancer stratification.
  • Targeted therapeutic strategies can be designed for ALK-positive cancer patients.
Keywords:
anaplastic large cell lymphomaanaplastic lymphoma kinasechimeric fusion proteinsmolecular targeted therapysignaling pathways

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...